Compare Neurocrine Biosciences Inc (NBIX) vs Thomson Reuters Corp (TRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Thomson Reuters Corp — how do they compare? Neurocrine Biosciences Inc trades at $179 (market cap $17.40B), while Thomson Reuters Corp trades at $90.7 (market cap $41.28B). The key difference: Thomson Reuters Corp is far larger — about 2.4× Neurocrine Biosciences Inc's market cap, and Thomson Reuters Corp pays a 2.75% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | TRI | |
|---|---|---|
Market Cap | $17.40B | $41.28B |
Sector | Health | Industrials |
52-Week High | $180.55 | $205.54 |
52-Week Low | $123.10 | $76.55 |
Enterprise Value | $16.49B | $43.24B |
Dividend Yield | — | 2.75% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Thomson Reuters Corp
Thomson Reuters is the result of the $17.6 billion megamerger of Canada's Thomson and the United Kingdom's Reuters Group in 2008 and the 2018 carve-out of its finance and risk business, Refinitiv, in which it holds a 45% stake. In 2019, the company agreed to exchange its 45% stake in Refinitiv for a 15% stake in LSE, which closed in early 2021. Since the divestiture, the company is more concentrated on selling its flagship legal data and software, Westlaw, and its tax accounting software, Onesource. Reuters sees roughly 80% of revenue and 70% of expenses attributed to the United States, while the remainder (largely through the global print and Reuters News segments) is distributed across Latin America, Europe, the Middle East, Africa, and Asia-Pacific.
Read more on TRI →
